Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy (2019)

Peer-Reviewed Study · Repici A; Wallace MB; East JE; Sharma P; Ramirez FC; Bruining DH; Young M; Gatof D; Canto MI; Marcon N; Cannizzaro R; Kiesslich R; Rutter M; Dekker E; Siersema PD; Spaander M; Kupcinskas L; Jonaitis L; Bisschops R; Radaelli F; Bhandari P; et al. · February 10, 2019

Repici A et al., 2019-02-10: Phase 3 randomized placebo-controlled trial in 1205 patients at 20 sites in Europe and the United States of an oral multimatrix methylene blue formulation (MB-MMX) given before screening colonoscopy. Adenoma detection rate rose from 47.81% with placebo to 56.29% with 200 mg MB-MMX, with more non-polypoid and small adenomas detected and no increase in removal of non-neoplastic lesions.

The ADR was higher for the MB-MMX group (273 of 485 patients, 56.29%) than the placebo group (229 of 479 patients, 47.81%)

Repici A et al., 2019-02-10: Phase 3 randomized placebo-controlled trial in 1205 patients at 20 sites in Europe and the United States of an oral multimatrix methylene blue formulation (MB-MMX) given before screening colonoscopy. Adenoma detection rate rose from 47.81% with placebo to 56.29% with 200 mg MB-MMX, with more non-polypoid and small adenomas detected and no increase in removal of non-neoplastic lesions. Study type: phase 3, double-blind, randomized, placebo-controlled trial. N=1205 randomized (485 in 200 mg MB-MMX, 479 placebo, remainder 100 mg masking arm). Countries: 20 sites in Europe and the United States. Dose/route: 200 mg oral MB-MMX tablet (100 mg arm for masking) with 4-L PEG bowel preparation. Comparator: placebo tablet. Primary endpoint: adenoma detection rate; absolute increase 8.5%. Secondary: non-polypoid lesions 43.92% vs 35.07% (OR 1.66), adenomas <=5 mm 37.11% vs 30.90%; no difference for polypoid or larger lesions; false-positive rate not different; severe adverse events 0.7% overall with no between-group difference. Registration: NCT01694966. Funder: not stated in abstract (Cosmo Technologies supplied MB-MMX per full text). Conflicts: not stated in abstract. This is oral MB, not sprayed dye, and is the strongest positive detection trial in the record. Study type: randomized trial.